Perrigo Company plc is a pure-play self-care company that develops, manufactures, and markets over-the-counter (OTC) health and wellness solutions. The company operates through two primary segments: Consumer Self-Care Americas, which focuses on the U.S. and Canada, and Consumer Self-Care International, which covers Europe and Australia. In North America, Perrigo provides store brand private label self-care products to major retail drug, supermarket, and mass merchandise chains, while also marketing a select lineup of national brands. In Europe, the portfolio consists primarily of consumer brands. The company’s product portfolio is diversified across categories including upper respiratory, healthy lifestyle, women's health, and infant formula. Notable brands include Opill, Mederma, Compeed, ellaOne, Solpadeine, Jungle Formula, and ACO. Perrigo was incorporated in 2013 as the successor to Perrigo Company, a Michigan corporation, following the acquisition of Elan Corporation, plc. The company traces its history back to 1887.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Household & Personal Products Homepage perrigo.com
Sector Consumer Defensive IR page investor.perrigo.com
Tags
over-the-counter, self-care, private label, store brands, consumer health, women's health, upper respiratory, infant formula, dermatology, pain relief, Opill, Mederma, Compeed, ellaOne, Solpadeine, Jungle Formula, ACO, Dr. Fresh, Firefly, Good Sense, Good Start, Nasonex, Plackers, Prevacid 24HR, REACH, Rembrandt, Steripod, Advantage, Elan Corporation
Press page investor.perrigo.com/press-releases

Metrics

Valuation  
Market cap $ 2.049B
Market cap (USD) $ 2.049B
P/E -1.18
PEG —
P/BV 0.84
P/S 0.50
P/OCF 8.51
P/FCF 12.18
Dividend yield 7.9%
Turnover / mcap —
Returns  
ROE -39.3%
ROI -21.7%
ROIC -12.8%
Profit margin -33.5%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 135.0%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score -50.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 4.253B 4.373B 4.656B 4.452B 4.139B 5.063B 4.837B 4.732B 4.946B 5.281B 4.604B 4.061B 3.54B
Net profit -1.425B -171.8M -12.7M -140.6M -68.9M -162.6M 146.1M 131M 119.6M -4.013B 128M 205.3M 441.9M
Free cash flow 145.1M 244.6M 303.8M 210.9M 4.2M 465.8M 250.1M 490.4M 610.3M 548.7M 1.061B 521.9M 449.7M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 13.92 25.71 32.18 34.09 38.9 44.72 51.66 38.75 87.16 83.23 184.83 145.76 120.93
Price performance 12m -0.46 -0.2 -0.06 -0.12 -0.13 -0.13 0.33 -0.56 0.05 -0.42 0.27 0.21 —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 1.18B 1.13B 1.07B 1.24B 1.05B 653M 697M 740M 642M 613M
↳ YoY growth -1.4% -3.8% -5.1% +15.9% -15.2% -38.1% +6.8% +6.1% -13.2% -4.6%
↳ 5y CAGR +6.9% +6.1% -2.4% -11.1% -9.2% -7.2% -12.4% -10.3%
Borrowings, current (USD) 573M 70.4M 190M 3.4M 37.8M 604M 36.2M 441M 36.4M 36.6M
Borrowings, non-current (USD) 5.22B 3.27B 3.05B 3.37B 3.53B 2.92B 4.07B 3.63B 3.58B 3.6B
Lease liabilities (USD) — — 167M 134M 193M 199M 239M 202M 195M 191M
Cash and deposits (USD) 622M 679M 551M 354M 642M 1.86B 601M 751M 559M 532M
Intangible assets (USD) 4.53B 4.75B 4.43B 4.75B 5.03B 3.68B 5.01B 5B 4.5B 4.76B
Right-of-use assets (USD) — — 164M 130M 186M 167M 217M 184M 175M 168M
Net debt (borrowings + leases - cash) (USD) 5.18B 2.66B 2.69B 3.15B 3.12B 1.85B 3.74B 3.52B 3.25B 3.3B
Cash flow detail
Operating cash flow (USD) 655M 699M 593M 388M 636M 156M 307M 406M 363M 239M
Purchases of property, plant and equipment (USD) -106M -88.6M -103M -138M -170M -152M -96.4M -102M -118M -93.4M
Purchases of intangible assets (USD) -65.1M 0.00 -35.6M — — — — — — —
Change in receivables (cash effect) (USD) -600,000 3.2M 21M -141M 169M -160M 100,000 -57.1M -11.1M 30.7M
Change in inventories (cash effect) (USD) 101M -16M -98.6M -67M -171M -2.4M -76.7M 19.4M 13.7M -61.1M
Change in payables (cash effect) (USD) -75.7M -39.6M 28.8M 17M -2.7M -7.9M 100M -65.9M 54.2M -28.7M
Dividends paid (cash effect) (USD) -83.2M -91.1M -105M -112M -124M -130M -142M -150M -153M -159M
Share buybacks (cash effect) (USD) 0.00 -192M -400M 0.00 -164M 0.00 0.00 — — —
Interest paid (cash effect) (USD) -205M -188M -134M -137M -146M -133M -217M -277M -251M -202M
Income taxes paid (cash effect) (USD) -140M -187M -144M -136M -81.2M -448M -100M -108M -156M -78.7M
Share-based compensation (USD) 23M 43.8M 37.7M 52.2M 58.5M 60.1M 54.9M 68.8M 64.4M 54.6M
Operating cash flow before change in receivables (USD) 656M 696M 572M 529M 467M 316M 307M 463M 374M 208M
Free cash flow (OCF - PPE - intangibles) (USD) 484M 610M 455M 250M 466M 4.2M 211M 304M 245M 145M
Income detail
Research and development expense (USD) 184M 168M 219M 187M 178M 122M 123M 123M 112M 95.4M
↳ 5y CAGR -7.9% -6.0% -10.9% -9.8% -11.7%
Total comprehensive income (USD) -4.08B 455M -36.5M 201M 93M -428M -203M 25M -345M -1.26B
Comprehensive income to owners (USD) -4.08B 455M -36.5M 201M 93M -428M -203M 25M -345M -1.26B
Provision for credit losses (USD) — — — — 2.9M 4M 3.2M 1.1M 1.2M 2.5M
Credit cost ratio (credit losses / average receivables) (%) — — — — 0.3% 0.5% 0.5% 0.2% 0.2% 0.4%
Reported May 22, 2017 Mar 1, 2018 May 9, 2019 Feb 27, 2020 Mar 1, 2021 Mar 1, 2022 Feb 28, 2023 Feb 27, 2024 Feb 28, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

  • PDF

  • Execution of Three-S plan driving sequential improvement in operating results and market share gains across U.S. Store Brand OTC and key European brands

  • Infant Formula divestiture expected to simplify portfolio and sharpen focus on higher-return consumer self care categories; strategic review of Oral Care business remains ongoing

  • Updated full-year 2026 outlook to reflect divestiture, more measured retailer inventory positioning, and continued softness in Europe

DUBLIN, Nov. 4, 2026 /PRNewswire / -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of consumer self-care products_,_ today announced financial results from continuing operations for the third quarter ended September 26, 2026.

Perrigo Company

"Our Three-S plan is delivering continued progress in the areas of the business within our control," said Albert Manzone, Interim President and Chief Executive Officer. "We gained market share again in U.S. store brand OTC and in key European brands. Category trends improved sequentially, which, combined with disciplined cost management, helped offset a difficult consumer backdrop.

"The sale of Infant Formula is an important step in evolving Perrigo into a more focused consumer self-care company. It is expected to enhance our margin profile, materially reduce expected future capital expenditures, and support continued deleveraging and reinvestment in the business. The result will be a simpler Perrigo, better positioned for profitable growth.

"We have adjusted our full-year outlook to reflect the divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in Europe. Our underlying model, combining scaled brands and store brands in categories people need every day, remains unchanged, and the actions we are taking to simplify Perrigo are positioning us for more consistent and profitable growth over the long term."

Third Quarter Results

All In**(1)** Core**(1)**
3Q'26 3Q'25 Change 3Q'26 3Q'25 Change
Reported Net Sales $989 $1,043 (5.2) % $908 $924 (1.7) %
Reported Gross Margin 32.4 % 36.1 % (370)bps
Reported Operating Margin 2.3 % 7.0 % (460)bps
Reported Diluted Earnings Per Share ("EPS") $(0.10) $0.09 n/m
All In Core
3Q'26 3Q'25 Change 3Q'26 3Q'25 Change
Organic Net Sales(2) $994 $1,013 (1.9) % $913 $924 (1.1) %
Adj. Gross Margin 36.3 % 39.9 % (370)bps 37.9 % 39.4 % (140)bps
Adj. Operating Margin 13.1 % 16.6 % (360)bps 14.3 % 16.5 % (210)bps
Adj. Diluted EPS $0.60 $0.80 (25.0) % $0.61 $0.67 (9.0) %
*  Absolute amounts in millions. Data may not add due to rounding. Percentages are based on actuals.
(1) As previously announced, the Company now reports results on both an All In and Core Perrigo basis. All In results reflect the entirety of our business, while Core represents our go-forward business and excludes Infant Formula and previously announced divestitures.
(2) See attached Appendix for details. Change in net sales on an organic basis excludes the effects of acquisitions, divestitures and exited products, and the impact of currency.

Net Sales

  • Core net sales were $908 million, declining 1.7% year-over-year, while Core organic net sales decreased 1.1%. Results reflected lower consumption in our Self Care segment, which led to more measured retailer inventory positioning ahead of the cough and cold season within the Upper Respiratory and Pain & Sleep categories. Performance was also impacted by lower contract manufacturing volumes. Partially offsetting those factors were continued share gains across U.S. Store Brand OTC and key European brands, supported by innovation and enhanced consumer marketing initiatives. Pricing decreased 0.4% and volume/mix decreased 0.7%.
  • All In reported net sales declined 5.2% year-over-year to $989 million. All In results were primarily driven by the same factors as Core net sales in addition to the year-over-year impact of divestitures and lower Infant Formula net sales.

Gross Margin

  • Reported All In gross margin was 32.4%, a decrease of 370 basis points.
  • Core adjusted gross margin decreased 140 basis points to 37.9% driven by lower net sales volumes and unfavorable mix. These headwinds were partially offset by the net recognition of a recovery of a portion of previously paid tariffs and continued market share gains.
  • All In adjusted gross margin decreased 370 basis points to 36.3%, driven by the same factors impacting Core adjusted gross margin in addition to the impact of divestitures and lower Infant Formula gross margin, which included the impact of planned under absorption.

Operating Margin

  • Reported operating margin was 2.3%, a decrease of 460 basis points.
  • Core adjusted operating margin decreased 210 basis points to 14.3% due to unfavorable gross profit flow through and higher operating expenses, primarily driven by increased advertising and promotional investments and the normalization of variable employee compensation. This decline was partially offset by benefits from the Operational Enhancement Program.
  • All In adjusted operating margin decreased 360 basis points to 13.1%, driven by the same factors impacting Core adjusted operating margin as well as the impact of divestitures and Infant Formula.

Other Items

  • Reported interest and other expense decreased $9.0 million to $41.2 million.
  • Net adjusted interest and other expense increased $0.5 million to $41.2 million.
  • The Company's reported effective tax rate was 21.1%. The Company's adjusted effective tax rate decreased to 3.5%, reflecting changes in the jurisdictional mix of earnings.

Diluted EPS

  • Reported diluted EPS was $(0.10) compared to $0.09 in the prior year.
  • Core adjusted EPS declined $0.06 to $0.61, a 9.0% decrease from the prior year. Results were impacted by a reduction in net sales and operating income, partially offset by a lower effective tax rate, which benefited results by $0.10.
  • All In adjusted diluted EPS declined $0.20 to $0.60, a 25.0% decrease from the prior year due to the same factors impacting Core adjusted EPS in addition to the impact of divestitures and Infant Formula. Results also reflected approximately $0.12 of unfavorable EPS impact from planned under absorption within Infant Formula.             

Business Segment Results

3Q'26 3Q'25 Change Organic Change
Segment net sales:
Self Care $613 $633 (3.2) % (2.8) %
Specialty Care 182 191 (4.6) % (3.5) %
Infant Formula 81 89 (9.6) % (9.5) %
Total segment net sales 876 914 (4.1) % (3.6) %
All Other 113 130 (13.1) % 14.0 %
Consolidated net sales $989 $1,043 (5.2) % (1.9) %
3Q'26 3Q'25 Change
Segment adjusted operating income:
Self Care $105 $131 (19.4) %
Specialty Care 32 42 (24.2) %
Infant Formula (1) 15 n/m
Total segment adjusted operating income $137 $187 (27.0) %
All Other 27 23 18.4 %
Unallocated (34) (36) (6.1) %
Consolidated adjusted operating income $129 $173 (25.5) %

*  Absolute amounts in millions. Amounts may not sum due to rounding. Percentages are based on actuals.

Self Care
Net sales decreased 3.2% compared to the prior year, inclusive of a 0.2% unfavorable impact of currency translation. Results reflected lower consumption, which led to more measured retailer inventory positioning ahead of the cough and cold season within the Upper Respiratory and Pain & Sleep categories. Performance was also impacted by lower contract manufacturing volumes and the unfavorable impact of pricing. These pressures were partly offset by growth in the Healthy Lifestyle category, driven by continued share gains of store brand nicotine replacement products, and the Digestive Health category, supported by higher volumes of store brand laxative products.

Segment adjusted operating income decreased 19.4%, primarily due to unfavorable gross profit flow through driven by unfavorable production variances, unfavorable mix, and higher advertising and promotional investments. These pressures were partially offset by benefits from the Operational Enhancement Program.

Specialty Care
Net sales decreased 4.6% compared to the prior year, inclusive of a 1.1% unfavorable impact of currency translation. Women's Health delivered strong growth, led by solid momentum and share gains for ellaOne_®_ and continued growth from Opill_®. Within the Skin Health category, strong in-season performance from Compeed_® and Jungle Formula_®_ was more than offset by lower sales of store brand and contract manufactured Minoxidil in addition to lower net sales of Mederma_®_.

Segment adjusted operating income decreased 24.2% due to unfavorable production variances, unfavorable mix in Skin Health, and higher advertising and promotional investments across the segment. These pressures were partially offset by benefits from the Operational Enhancement Program.

Infant Formula
Net sales decreased 9.6% compared to the prior year. Growth in store brand infant formula was more than offset by expected lower contract manufacturing volumes, reflecting the shift of certain contract formula shipments that were recorded in the second quarter.

Segment adjusted operating income decreased primarily due to unfavorable gross profit flow through, including planned under absorption, which was partially offset by lower operating expenses.

All Other
Net sales decreased 13.1%, inclusive of a 1.2% unfavorable impact of currency translation, primarily due to the impact of divestitures.

Segment adjusted operating income increased 18.4% due to the net recognition of a recovery of a portion of previously paid tariffs, in addition to improved productivity and lower operating expenses in the Oral Care category. These factors more than offset the impact of divestitures.

Cash Flow and Balance Sheet

  • Net cash from operating activities was $96 million in the third quarter.
  • Third quarter capital expenditures were $18 million and the Company returned $40 million to shareholders through dividends.
  • Cash and cash equivalents as of September 26, 2026 were $437 million while total debt was $3.3 billion.
  • Subsequent to quarter-end, the Company announced an agreement to divest its Infant Formula business for total consideration of up to $175 million. The transaction consideration consists of $40 million in upfront cash at closing and up to an additional $135 million contingent on the achievement of net sales milestones through 2030. Net proceeds are expected to be deployed in accordance with Perrigo's capital allocation priorities. The divestiture is expected to simplify our portfolio and sharpen our focus on higher-return consumer self care categories, while enhancing the Company's margin profile. After considering expected carrying value relative to cash proceeds and an estimate of fair value of the contingent milestones, we expect to recognize an impairment loss between $275.0 million and $375.0 million resulting from the measurement as held for sale during the fourth quarter of 2026.

Fiscal 2026 Outlook

Beginning with the fourth quarter and full-year 2026 reporting, the Infant Formula business will be reported as discontinued operations. Accordingly, the Company's All In outlook no longer includes Infant Formula but continues to include other divested businesses. The Company's Core outlook continues to exclude Infant Formula and previously-announced divestitures. For fiscal 2026, the Company has updated its outlook and related assumptions to reflect the Infant Formula divestiture, more measured retailer inventory positioning ahead of the cough and cold season, and continued softness in the European consumer environment. 

All In****1 ExDivestitures Core****2 ForeignCurrency Organic
Net Sales Growth YoY (5.7)% to (4.6)% ~210 bps (3.6)% to (2.5)% (0.2) % (3.8)% to (2.7)%
Adj. Gross Margin 37.8% to 38.8% ~(30) bps 37.5% to 38.5%
Adj. Operating Margin 14.3% to 15.3% ~(30) bps 14.0% to 15.0%
Adj. EPS $2.25 to $2.45 ~$(0.10) $2.15 to $2.35

Other assumptions****3

  • Net interest expense of approximately $162 million.
  • Adjusted effective tax rate of approximately 14.0%.
  • Adjusted weighted average shares outstanding of approximately 140 million.
  • Net leverage of approximately 4.0 times adjusted EBITDA.
  • Cash from operating activities as a percentage of adjusted net income in the low-to-mid-60% range.
(1) Prior All In guidance included Infant Formula results and reflected net sales growth YoY of (5.5)% to (1.5)%, adjusted gross margin of 36.5% to 37.5%, adjusted operating margin of 12.5% to 13.5%, and adjusted EPS of $2.00 to $2.30.
(2) Prior Core guidance excluded Infant Formula results and previously announced divestitures and reflected net sales growth YoY of (3.0)% to 1.0%, adjusted gross margin of 39.0% to 40.0%, adjusted operating margin of 15.0% to 16.0%, and adjusted EPS of $2.25 to $2.55.
(3) Prior other assumptions reflected net interest expense of $156M, adjusted effective tax rate of ~18%, adjusted weighted shares outstanding of 139.3M, net leverage at, or slightly lower than, approximately 4.0 times adjusted EBITDA, and cash from operating activities as a percentage of adjusted net income in the mid-60% range.

Webcast and Conference Call Information

Perrigo previously announced that management will host a call/webcast to discuss its third quarter 2026 financial results beginning at 08:30 A.M. (ET) Wednesday, November 4, 2026. The call will be available live via webcast to interested parties in the investor relations section of the Perrigo website at http://perrigo.investorroom.com/events-webcasts or by phone at 800-836-8184, International 646-357-8785, and reference ID # 91025. A taped replay of the call will be available beginning at approximately 12:00 P.M. (ET) Wednesday, November 4, until midnight Wednesday, November 11, 2026. To listen to the replay, dial 888-660-6345, International 646-517-4150, and use access code 91025#.

About Perrigo

Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

  • PDF

  • Advances Streamline pillar of Perrigo's Three-S plan through portfolio simplification

  • Furthers Perrigo's evolution into a simpler, more focused consumer self-care company

  • Expected to enhance Perrigo's margin profile and eliminate significant expected future capital expenditures

  • Aligns reported results more closely with the financial profile of Core Perrigo

  • MeridianMade's infant-grade, American manufacturing infrastructure and operating capabilities will support the continued supply of safe, high-quality, and affordable infant nutrition

DUBLIN, Oct. 29, 2026 /PRNewswire / -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or "the Company"), a leading provider of consumer self-care products, today announced that it has entered into a definitive agreement pursuant to which MeridianMade, an American contract manufacturing platform dedicated to infant nutrition, will acquire Perrigo's Infant Formula business for total consideration of up to $175 million. The transaction consists of $40 million in cash at closing and up to an additional $135 million contingent on the achievement of future performance milestones through 2030.

Perrigo Company

This divestiture advances Perrigo's evolution into a more focused consumer self-care company with a diversified portfolio of OTC products addressing essential, everyday health needs. The agreement follows a comprehensive review of strategic alternatives for the Infant Formula business and reflects careful consideration of the best path forward for the business and its stakeholders. MeridianMade is a company built entirely around infant nutrition with a singular focus on providing safe, high-quality formula to families and caregivers, with the infant-grade, domestic infrastructure and operating capabilities to support that aim.

"Today's announcement marks an important milestone in advancing the Streamline pillar of our Three-S plan to Stabilize, Streamline, and Strengthen the business," said Albert Manzone, Interim President and Chief Executive Officer. "For Perrigo, this transaction is expected to enhance our margin profile, materially reduce expected future capital expenditures, and enable us to concentrate resources on strengthening our core consumer self-care portfolio. Our Infant Formula colleagues have worked with tremendous dedication to enhance performance and improve operations, which has positioned Infant Formula well for its next chapter. We are confident that with its singular focus on infant nutrition and commitment to quality, safety, and continuity, MeridianMade is the right manufacturer to carry this important category forward."

Ron Belldegrun, CEO of MeridianMade, and Mia Funt, President of MeridianMade, said, "This acquisition is a commitment to responsible stewardship of store-brand infant formulas, which offer American families a more affordable option for safe, high-quality infant nutrition. We look forward to working with the Perrigo team throughout the transition and continuing to support this critical source of infant nutrition."

Until closing, Perrigo's Infant Formula business and MeridianMade will continue to operate as independent companies, and Perrigo will continue to own and operate the Infant Formula business with the same focus on safety, quality, reliable supply, and customer service. Closing is expected in the first half of 2027. The transaction is subject to the satisfaction of customary closing conditions and regulatory approvals.

As a result of the transaction, Perrigo's future reported results are expected to more closely reflect the financial profile of Core Perrigo, which Perrigo management believes will provide a clearer view of its ongoing business. Core Perrigo excludes Infant Formula and certain previously announced divestitures and exited products. Infant Formula will continue to be reported in All In results for the third quarter of 2026. Beginning in the fourth quarter of 2026, Infant Formula will be included in discontinued operations. In connection with the announced transaction, the Company expects to record a non-cash impairment charge in the fourth quarter of 2026 in the range of $275 to $375 million. In the trailing four quarters ended June 27, 2026, Infant Formula generated net sales of $380 million and segment adjusted operating income of $8 million. The transaction is expected to significantly reduce Perrigo's future capital expenditure requirements.

Net proceeds from the transaction are expected to be used in accordance with Perrigo's capital allocation priorities.

Goldman Sachs is serving as financial advisor and A&O Shearman is serving as legal advisor for Perrigo. Jefferies LLC is serving as financial advisor and Sullivan and Cromwell LLP is serving as legal advisor to MeridianMade.

About Perrigo 
Perrigo Company plc (NYSE: PRGO) is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. For more information, visit www.perrigo.com .

**About MeridianMade
**MeridianMade is a domestic, infant-focused nutrition platform dedicated to the development and manufacturing of high-quality infant formula. MeridianMade's contract manufacturing services include spray drying, dry blending and packaging capabilities, supported by in-house R&D, clinical research, regulatory navigation and commercialization. For more information, visit https://meridianmade.us/ .

Forward-Looking Statements
Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our, or our industry's actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by any forward-looking statements. In particular, statements about the proposed divestiture of the Company's Infant Formula business, including the timing and benefits thereof and the anticipated use of proceeds, our expectations, beliefs, plans, objectives, assumptions, future events or future performance contained in this press release are forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "forecast," "predict," "potential" or the negative of those terms or other comparable terminology.

We have based these forward-looking statements on our current expectations, assumptions, estimates and projections. While we believe these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond our control, including our ability to complete the proposed divestment of the Infant Formula business, receipt of third-party approvals regarding the transaction, performance by counterparties to the transaction and the likelihood of satisfying the deferred payment milestones associated with the transaction, among others. These and other important factors, including those discussed in our Form 10-K for the year ended December 31, 2025 and in any subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Perrigo Contacts
**Eric Jacobson, Vice President, Global Investor Relations
(616) 886-0375, [email protected]  

Nick Gallagher, Associate Director, Global Investor Relations
(269) 686-3238, [email protected]  

**MeridianMade Contact
**[email protected]  

SOURCE Perrigo Company plc

×

logo

     

Come work for a leading global self-care company

Perrigo Careers

Company

Consumer Products

Corporate Responsibility

News & Media

Investor Relations

Supplier Website

Contact Us

Perrigo Employees  Patent Resources  Privacy Notice  Cookie Statement  Cookie List  Policies and Practices  Terms & Conditions  US Company Store Contact   
© 2026 Perrigo Company plc, All Rights Reserved.

Your Privacy Rights

×

(opens in a new window)

Prompts

Perrigo Company plc (ticker PRGO), listed in United States.

Company History

Date Change Detail
— Predecessor Predecessor Perrigo Co (CIK 820096) filed under its own registration; its figures are on its own company page, not shown here.

ETFs Holding Perrigo Company plc

ETF Weight in ETF Shares Market value As of
DIVY 4.62% 85,869 $ 1.389M Nov 17, 2026
FSCC 0.91% 227,032 $ 3.324M Aug 31, 2026
KDVD 0.90% 7,313 $ 75.982K Jun 30, 2026
FTKI 0.57% 8,997 $ 145.571K Nov 16, 2026
CVAR 0.43% 18,133 $ 183.325K Jul 31, 2026
BSVO 0.37% 571,369 $ 9M Nov 18, 2026
CDX short -0.25% -38,831.0737 $ -611.978K Nov 17, 2026
AVUV 0.24% 4,863,882 $ 78.698M Nov 16, 2026
VFVA 0.19% 126,427 $ 1.851M Aug 31, 2026
DFSV 0.11% 1,916,294 $ 31.006M Nov 12, 2026
AVSC 0.10% 197,144 $ 3.19M Nov 16, 2026
DFAT 0.07% 1,363,941 $ 22.069M Nov 12, 2026
AFMC 0.05% 8,098 $ 131.026K Nov 16, 2026
AVUS 0.01% 69,389 $ 1.123M Nov 16, 2026
AVIE 0.01% 122 $ 1,973.96 Nov 16, 2026
DFAS 0.01% 200,679 $ 3.247M Nov 12, 2026
DFAC 0.01% 365,062 $ 5.907M Nov 12, 2026
DXUV 0.00% 11,412 $ 184.646K Nov 12, 2026
DCOR 0.00% 65,467 $ 1.059M Nov 12, 2026
DFSU 0.00% 1,796 $ 29.059K Nov 12, 2026
DFAU 0.00% 5,674 $ 91.805K Nov 12, 2026
DFUS 0.00% 8,792 $ 142.255K Nov 12, 2026
AVSU 0.00% 273 $ 4,417.14 Nov 16, 2026